Psychedelic Compound MEAI

EXCLUSIVE: Clearmind Medicine Secures Approval To Launch Clinical Trial For Alcohol Addiction Treatment

Next-Gen Israeli Psychedelics Company Gears Up For Trial Targeting Alcohol Addiction

Psyched Clinical Trials: Australian Univ. Pursues MDMA, MEAI Compound About To Set Off

Next-Gen Israeli Psychedelics Company Gears Up For Trial Targeting Alcohol Addiction

Psyched Clinical Trials: Australian Univ. Pursues MDMA, MEAI Compound About To Set Off

A Drug That Mimics Alcohol Buzz Is Bound For Human Trials: Here's What's Next

EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead

A Drug That Mimics Alcohol Buzz Is Bound For Human Trials: Here's What's Next

EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead

EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When

EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains

Psychedelic Compound MEAI Recent News

Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction

(Part one of a four-part series) Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to major innovative heights.

Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know

Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd.